Five years after the World Health Organization declared COVID-19 a global pandemic, infectious disease experts continue to draw on its lessons for future disasters.

The majority of RSV infections in young children are managed in primary care, however, the disease burden in this setting remains poorly defined.

Use these materials to raise awareness about new immunisation products to protect infants in early life from a top cause of severe respiratory infections in children.

Strengthening of nonpharmaceutical interventions changed the epidemic dynamics of pediatric infectious diseases, with a trend toward older hospitalized children.

Some children and young people (CYP) infected with SARS-COV-2 experience impairing symptoms post-infection, known as post-COVID-19 condition (PCC).

From being a largely unknown pathogen, RSV is now almost a household word. New solutions, such as long-acting monoclonal antibodies and maternal vaccination, both recently recommended by WHO, could dramatically alter the RSV landscape.

This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, next steps are outlined to minimise the delay.

Respiratory syncytial virus (RSV) is a leading cause of hospitalization among young children. Historically, American Indian and Alaska Native (AI/AN) children have experienced high rates of RSV-associated hospitalization.